secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001104659-22-056278
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q1 revenue $1.567B (+8% ex-FX); adj. EPS $1.65; reaffirms FY guidance
-----------------------------------------------------------------------------

- Revenue $1,567M, +4% as-reported / +8% ex-FX vs Q1 2021; Women's Health -5%, Biosimilars +22%, Established Brands +10%.
- Net income from cont. ops $348M ($1.36 diluted EPS); adjusted net income $420M ($1.65 adj. diluted EPS).
- Adjusted EBITDA $647M; gross margin 64.2% (adj. 66.5%); board declares $0.28 quarterly dividend.
- Full year 2022 financial guidance reaffirmed; acquired rights to Marvelon/Mercilon and Xaciato license in certain markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922056278/0001104659-22-056278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922056278/tm2214364d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-056278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer